# A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

> **NCT02005471** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 389 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Venetoclax
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02005471
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-17
- **Primary completion:** 2017-05-08
- **Final completion:** 2022-08-03
- **Target enrollment:** 389 (ACTUAL)
- **Last updated:** 2023-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02005471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02005471, "A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02005471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*